June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Noninvasive objective diagnosis and monitoring of patients with focal intracranial pathology based on pupil response for focal chromatic light stimuli.
Author Affiliations & Notes
  • Ygal Rotenstreich
    Goldscheleger Eye Research Institute, Sheba Medical Center, Tel Hashomer, Israel
  • Amit Hamburg
    Goldscheleger Eye Research Institute, Sheba Medical Center, Tel Hashomer, Israel
  • Ifat Sher-Rosenthal
    Goldscheleger Eye Research Institute, Sheba Medical Center, Tel Hashomer, Israel
  • Anton Wohl
    Department of Neurosurgery, Sheba Medical Center, Tel Hashomer, Israel
  • Zvi Cohen
    Department of Neurosurgery, Sheba Medical Center, Tel Hashomer, Israel
  • Footnotes
    Commercial Relationships   Ygal Rotenstreich, Sheba Medical Center (P); Amit Hamburg, None; Ifat Sher-Rosenthal, Sheba Medical Center (P); Anton Wohl, Sheba Medical Center (P); Zvi Cohen, Sheba Medical Center (P)
  • Footnotes
    Support  Israeli Defence Force reserach grant
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 5098. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ygal Rotenstreich, Amit Hamburg, Ifat Sher-Rosenthal, Anton Wohl, Zvi Cohen; Noninvasive objective diagnosis and monitoring of patients with focal intracranial pathology based on pupil response for focal chromatic light stimuli.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):5098.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To characterize rod-, cone- and melanopsin-mediated pupil light responses (PLR) for small focal chromatic light stimuli presented in peripheral and central retinal locations in patients with brain tumors.

Methods : Eighteen patients with brain tumors and 32 age-similar controls were enrolled. Patients were divided into 2 groups: group I included 10 patients with brain tumors with no apparent contact with the optic apparatus; group II included 8 patients with brain tumors that contacted the optic apparatus. The PLR for small (0.43°) blue and red light stimuli presented at peripheral (21°) and central (4.2°) visual field locations were measured using a chromatic pupilloperimeter under mesopic light adaptation conditions. All subjects underwent a complete ophthalmic exam, standard Humphrey automated perimetry (24-2), color vision test, best-corrected visual acuity, and refraction as well as Spectral-Domain Optical Coherence Tomography (SD-OCT) imaging. All patients underwent brain MRI.

Results : The SD-OCT thicknesses of macular ganglion cell and inner plexiform layers, as well as peripapillary retinal nerve fiber layer, were within normal limits in all patients. The mean normalized pupil size at 3.7sec following blue light offset recorded in patients from both groups was significantly higher compared with controls in central and peripheral locations (all Ps< 0.003). ROC analysis revealed that this PLR parameter had the largest area under the curve (AUC) in the central retina in group I and in the peripheral retina in group II (90.8%, p=0.003 and 89.3%, p=0.003, respectively). In group II, ROC analysis revealed that the maximal contraction velocity recorded in response to the red light stimulus in the peripheral superior test target had the largest AUC (96.4%, p=0.006).

Conclusions : Focal intracranial pathologies may be detected by localized melanopsin-mediated sustained PLR for central blue stimulus. Patients with brain tumors involving the visual pathway had an additional defect in the cone-mediated PLR. Quantification of the PLR for focal central and peripheral chromatic stimuli may serve as a novel noninvasive objective diagnostic tool for focal intracranial pathologies.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×